Raltegravir  ||| S:0 E:12 ||| NNP
in  ||| S:12 E:15 ||| IN
treatment  ||| S:15 E:25 ||| NN
naive  ||| S:25 E:31 ||| JJ
patients  ||| S:31 E:40 ||| NNS
Raltegravir  ||| S:40 E:52 ||| NNP
is  ||| S:52 E:55 ||| VBZ
the  ||| S:55 E:59 ||| DT
first  ||| S:59 E:65 ||| JJ
integrase  ||| S:65 E:75 ||| NNS
inhibitor  ||| S:75 E:85 ||| VBP
approved  ||| S:85 E:94 ||| VBN
for  ||| S:94 E:98 ||| IN
the  ||| S:98 E:102 ||| DT
treatment  ||| S:102 E:112 ||| NN
of  ||| S:112 E:115 ||| IN
HIV  ||| S:115 E:119 ||| NNP
infection  ||| S:119 E:129 ||| VBD
based  ||| S:129 E:135 ||| VBN
on  ||| S:135 E:138 ||| IN
the  ||| S:138 E:142 ||| DT
superior  ||| S:142 E:151 ||| JJ
efficacy  ||| S:151 E:160 ||| NN
it  ||| S:160 E:163 ||| PRP
showed  ||| S:163 E:170 ||| VBD
compared  ||| S:170 E:179 ||| VBN
to  ||| S:179 E:182 ||| TO
optimized  ||| S:182 E:192 ||| VB
backbone  ||| S:192 E:201 ||| JJ
therapy  ||| S:201 E:209 ||| NN
alone  ||| S:209 E:215 ||| RB
in  ||| S:215 E:218 ||| IN
patients  ||| S:218 E:227 ||| NNS
harboring  ||| S:227 E:237 ||| VBG
multidrug  ||| S:237 E:247 ||| JJ
resistant  ||| S:247 E:257 ||| JJ
viruses ||| S:257 E:264 ||| NN
.  ||| S:264 E:266 ||| .
Studies  ||| S:266 E:274 ||| NNS
on  ||| S:274 E:277 ||| IN
naive  ||| S:277 E:283 ||| JJ
patients  ||| S:283 E:292 ||| NNS
showed  ||| S:292 E:299 ||| VBD
comparable  ||| S:299 E:310 ||| JJ
efficacy  ||| S:310 E:319 ||| NN
of  ||| S:319 E:322 ||| IN
raltegravir  ||| S:322 E:334 ||| NN
and  ||| S:334 E:338 ||| CC
efavirenz  ||| S:338 E:348 ||| NNS
and  ||| S:348 E:352 ||| CC
just  ||| S:352 E:357 ||| RB
recently  ||| S:357 E:366 ||| RB
the  ||| S:366 E:370 ||| DT
US  ||| S:370 E:373 ||| NNP
Food  ||| S:373 E:378 ||| NNP
and  ||| S:378 E:382 ||| CC
Drug  ||| S:382 E:387 ||| NNP
Administration  ||| S:387 E:402 ||| NNP
( ||| S:402 E:403 ||| -LRB-
FDA ||| S:403 E:406 ||| NNP
)  ||| S:406 E:408 ||| -RRB-
approved  ||| S:408 E:417 ||| VBD
raltegravir  ||| S:417 E:429 ||| VBN
for  ||| S:429 E:433 ||| IN
the  ||| S:433 E:437 ||| DT
use  ||| S:437 E:441 ||| NN
in  ||| S:441 E:444 ||| IN
naive  ||| S:444 E:450 ||| JJ
patients  ||| S:450 E:459 ||| NNS
based  ||| S:459 E:465 ||| VBN
on  ||| S:465 E:468 ||| IN
the  ||| S:468 E:472 ||| DT
favorable  ||| S:472 E:482 ||| JJ
results  ||| S:482 E:490 ||| NNS
of  ||| S:490 E:493 ||| IN
the  ||| S:493 E:497 ||| DT
international  ||| S:497 E:511 ||| JJ
double-blind  ||| S:511 E:524 ||| JJ
phase  ||| S:524 E:530 ||| NN
III  ||| S:530 E:534 ||| NNP
STARTMRK  ||| S:534 E:543 ||| NNP
trial ||| S:543 E:548 ||| NN
.  ||| S:548 E:550 ||| .
Additional  ||| S:550 E:561 ||| JJ
interesting  ||| S:561 E:573 ||| JJ
findings  ||| S:573 E:582 ||| NNS
were  ||| S:582 E:587 ||| VBD
the  ||| S:587 E:591 ||| DT
faster ||| S:591 E:597 ||| RBR
,  ||| S:597 E:599 ||| ,
and  ||| S:599 E:603 ||| CC
not  ||| S:603 E:607 ||| RB
yet  ||| S:607 E:611 ||| RB
explained ||| S:611 E:620 ||| VBD
,  ||| S:620 E:622 ||| ,
decay  ||| S:622 E:628 ||| NN
of  ||| S:628 E:631 ||| IN
HIV-1  ||| S:631 E:637 ||| NNP
RNA  ||| S:637 E:641 ||| NNP
and  ||| S:641 E:645 ||| CC
the  ||| S:645 E:649 ||| DT
higher  ||| S:649 E:656 ||| JJR
CD4+  ||| S:656 E:661 ||| NN
cells  ||| S:661 E:667 ||| NNS
increase  ||| S:667 E:676 ||| NN
in  ||| S:676 E:679 ||| IN
the  ||| S:679 E:683 ||| DT
raltegravir  ||| S:683 E:695 ||| JJ
group  ||| S:695 E:701 ||| NN
as  ||| S:701 E:704 ||| IN
compared  ||| S:704 E:713 ||| VBN
to  ||| S:713 E:716 ||| TO
the  ||| S:716 E:720 ||| DT
efavirenz  ||| S:720 E:730 ||| JJ
group ||| S:730 E:735 ||| NN
.  ||| S:735 E:737 ||| .
Raltegravir  ||| S:737 E:749 ||| NNP
is  ||| S:749 E:752 ||| VBZ
generally  ||| S:752 E:762 ||| RB
well  ||| S:762 E:767 ||| RB
tolerated  ||| S:767 E:777 ||| JJ
and  ||| S:777 E:781 ||| CC
adverse  ||| S:781 E:789 ||| JJ
events  ||| S:789 E:796 ||| NNS
were  ||| S:796 E:801 ||| VBD
generally  ||| S:801 E:811 ||| RB
similar  ||| S:811 E:819 ||| JJ
in  ||| S:819 E:822 ||| IN
raltegravir  ||| S:822 E:834 ||| NN
and  ||| S:834 E:838 ||| CC
comparator  ||| S:838 E:849 ||| JJ
arms  ||| S:849 E:854 ||| NNS
throughout  ||| S:854 E:865 ||| IN
all  ||| S:865 E:869 ||| DT
studies ||| S:869 E:876 ||| NNS
.  ||| S:876 E:878 ||| .
When  ||| S:878 E:883 ||| WRB
compared  ||| S:883 E:892 ||| VBN
to  ||| S:892 E:895 ||| TO
efavirenz ||| S:895 E:904 ||| VB
,  ||| S:904 E:906 ||| ,
patients  ||| S:906 E:915 ||| NNS
on  ||| S:915 E:918 ||| IN
raltegravir  ||| S:918 E:930 ||| NN
showed  ||| S:930 E:937 ||| VBD
less  ||| S:937 E:942 ||| JJR
incidence  ||| S:942 E:952 ||| NN
of  ||| S:952 E:955 ||| IN
central  ||| S:955 E:963 ||| JJ
nervous  ||| S:963 E:971 ||| JJ
system-related  ||| S:971 E:986 ||| JJ
adverse  ||| S:986 E:994 ||| JJ
events ||| S:994 E:1000 ||| NNS
.  ||| S:1000 E:1002 ||| .
In  ||| S:1002 E:1005 ||| IN
studies  ||| S:1005 E:1013 ||| NNS
on  ||| S:1013 E:1016 ||| IN
experienced  ||| S:1016 E:1028 ||| JJ
patients  ||| S:1028 E:1037 ||| NNS
higher  ||| S:1037 E:1044 ||| JJR
incidence  ||| S:1044 E:1054 ||| NN
of  ||| S:1054 E:1057 ||| IN
cancers  ||| S:1057 E:1065 ||| NNS
was  ||| S:1065 E:1069 ||| VBD
found  ||| S:1069 E:1075 ||| VBN
in  ||| S:1075 E:1078 ||| IN
the  ||| S:1078 E:1082 ||| DT
raltegravir  ||| S:1082 E:1094 ||| JJ
arm ||| S:1094 E:1097 ||| NN
:  ||| S:1097 E:1099 ||| :
a  ||| S:1099 E:1101 ||| DT
relationship  ||| S:1101 E:1114 ||| NN
with  ||| S:1114 E:1119 ||| IN
the  ||| S:1119 E:1123 ||| DT
drug  ||| S:1123 E:1128 ||| NN
was ||| S:1128 E:1131 ||| VBD
,  ||| S:1131 E:1133 ||| ,
however  ||| S:1133 E:1141 ||| RB
not  ||| S:1141 E:1145 ||| RB
confirmed  ||| S:1145 E:1155 ||| VBN
in  ||| S:1155 E:1158 ||| IN
a  ||| S:1158 E:1160 ||| DT
recent  ||| S:1160 E:1167 ||| JJ
review  ||| S:1167 E:1174 ||| NN
considering  ||| S:1174 E:1186 ||| VBG
all  ||| S:1186 E:1190 ||| DT
raltegravir  ||| S:1190 E:1202 ||| JJ
studies ||| S:1202 E:1209 ||| NNS
.  ||| S:1209 E:1211 ||| .
Raltegravir  ||| S:1211 E:1223 ||| NNP
also  ||| S:1223 E:1228 ||| RB
showed  ||| S:1228 E:1235 ||| VBD
a  ||| S:1235 E:1237 ||| DT
safe  ||| S:1237 E:1242 ||| JJ
lipid  ||| S:1242 E:1248 ||| JJ
profile  ||| S:1248 E:1256 ||| NN
especially  ||| S:1256 E:1267 ||| RB
in  ||| S:1267 E:1270 ||| IN
naive  ||| S:1270 E:1276 ||| JJ
patients ||| S:1276 E:1284 ||| NNS
,  ||| S:1284 E:1286 ||| ,
finding  ||| S:1286 E:1294 ||| VBG
that  ||| S:1294 E:1299 ||| IN
renders  ||| S:1299 E:1307 ||| VBG
the  ||| S:1307 E:1311 ||| DT
drug  ||| S:1311 E:1316 ||| NN
attractive  ||| S:1316 E:1327 ||| JJ
for  ||| S:1327 E:1331 ||| IN
patients  ||| S:1331 E:1340 ||| NNS
with  ||| S:1340 E:1345 ||| IN
other  ||| S:1345 E:1351 ||| JJ
cardiovascular  ||| S:1351 E:1366 ||| JJ
risk  ||| S:1366 E:1371 ||| NN
factors ||| S:1371 E:1378 ||| NNS
.  ||| S:1378 E:1380 ||| .
All  ||| S:1380 E:1384 ||| PDT
this  ||| S:1384 E:1389 ||| DT
characteristics  ||| S:1389 E:1405 ||| NN
in  ||| S:1405 E:1408 ||| IN
association  ||| S:1408 E:1420 ||| NN
with  ||| S:1420 E:1425 ||| IN
its  ||| S:1425 E:1429 ||| PRP$
specific  ||| S:1429 E:1438 ||| JJ
mechanism  ||| S:1438 E:1448 ||| NN
of  ||| S:1448 E:1451 ||| IN
action ||| S:1451 E:1457 ||| NN
,  ||| S:1457 E:1459 ||| ,
make  ||| S:1459 E:1464 ||| VBP
raltegravir  ||| S:1464 E:1476 ||| VBG
an  ||| S:1476 E:1479 ||| DT
interesting  ||| S:1479 E:1491 ||| JJ
drug  ||| S:1491 E:1496 ||| NN
for  ||| S:1496 E:1500 ||| IN
naive  ||| S:1500 E:1506 ||| JJ
patients  ||| S:1506 E:1515 ||| NNS
and  ||| S:1515 E:1519 ||| CC
a  ||| S:1519 E:1521 ||| DT
large  ||| S:1521 E:1527 ||| JJ
use  ||| S:1527 E:1531 ||| NN
in  ||| S:1531 E:1534 ||| IN
this  ||| S:1534 E:1539 ||| DT
type  ||| S:1539 E:1544 ||| NN
of  ||| S:1544 E:1547 ||| IN
patients  ||| S:1547 E:1556 ||| NNS
is  ||| S:1556 E:1559 ||| VBZ
predictable ||| S:1559 E:1570 ||| JJ
.  ||| S:1570 E:1572 ||| .
Only  ||| S:1572 E:1577 ||| JJ
time  ||| S:1577 E:1582 ||| NN
and  ||| S:1582 E:1586 ||| CC
experience ||| S:1586 E:1596 ||| NN
,  ||| S:1596 E:1598 ||| ,
however ||| S:1598 E:1605 ||| RB
,  ||| S:1605 E:1607 ||| ,
will  ||| S:1607 E:1612 ||| MD
tell  ||| S:1612 E:1617 ||| VB
us  ||| S:1617 E:1620 ||| PRP
whether  ||| S:1620 E:1628 ||| IN
raltegravir  ||| S:1628 E:1640 ||| NNS
will  ||| S:1640 E:1645 ||| MD
maintain  ||| S:1645 E:1654 ||| VB
its  ||| S:1654 E:1658 ||| PRP$
promises  ||| S:1658 E:1667 ||| NNS
in  ||| S:1667 E:1670 ||| IN
the  ||| S:1670 E:1674 ||| DT
long  ||| S:1674 E:1679 ||| JJ
run ||| S:1679 E:1682 ||| NN
.  ||| S:1682 E:1684 ||| .
